The dependence of mesenchymal cell lines on the GAS6-AXL axis renders them sensitive to pharmacologic inhibition of AXL, and activity has been shown with the small molecule AXL kinase inhibitor bemcentinib across various cancer types including non-small cell lung cancer, mesothelioma and acute myeloid leukaemia [29–32]. Here, AXL is linked to cancer.